<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412802</url>
  </required_header>
  <id_info>
    <org_study_id>2006-01</org_study_id>
    <nct_id>NCT00412802</nct_id>
  </id_info>
  <brief_title>Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome</brief_title>
  <official_title>Validation of Enoxaparin Dose Adaptation in Patients With Moderate Renal Failure Hospitalized for an Acute Coronary Syndrome, the VALIDE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Cardiology Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Cardiology Society</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the VALIDE study is to validate that a 25% dose reduction of enoxaparine in
      patients with moderate renal failure (creatinine clearance between 30 and 50 ml/min) and
      hospitalized for an acute coronary syndrome provides at steady state a similar anti Xa level
      in plasma compared to that obtained in patients without renal failure and receiving the usual
      dose of 1 mg/kg subcutaneously every 12 hours. 140 per - protocol patients are planned to be
      included.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Included patients will be those hospitalized for an acute coronary syndrome with indication
      of enoxaparin treatment. A same initial dose of 1 mg/kg will be administrated to all
      patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously)
      will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30
      and 50 ml/min. After the fourth dose, the anti-Xa plasma levels (main endpoint) will be
      measured at peak (between 3 and 5 hours after dose administration). Residual values of antiXa
      will also be measured before the fifth dose administration (secondary criteria).

      The objective is to demonstrate a bio-equivalence of efficacy on the anti-Xa values obtained
      in patients with moderate rela failure compared with patients with creatinine clearance
      higher than 50 ml/min.

      Thrombotic and bleeding events will be recorded during hospitalisation. 140 per-protocol
      evaluable consecutive patients will have to be obtained: 70 with creatinine clearance higher
      than 50 ml/min and 70 patients with creatinin clearance between 30 and 50 ml/min.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma antiXa levels at peak after the fourth enoxaparine dose administration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>residual plasma antiXa level before the fifth enoxaparine dose administration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>activated thromboplastin time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thrombotic events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dose adaptation of Enoxaparine at the renal deficient patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No dose adaptation of Enoxaparine at renal normal patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dose adaptation of Enoxaparin</intervention_name>
    <description>A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal injection of Enoxaparine</intervention_name>
    <description>No dose adaptation of Enoxaparine</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients hospitalized for acute coronary syndrome

          -  Indication of enoxaparin treatment

          -  Informed consent

        Exclusion Criteria:

          -  Myocardial infarction with ST elevation

          -  Inclusion later than 12 hours after the first enoxaparin dose administration

          -  Creatinine clearance lower than 30 ml/min

          -  History of thrombopenia induced by heparin

          -  Platelet count lower than 100.000 / mm3

          -  Age &lt; 18

          -  Pregnancy

          -  History of hemorrhagic stroke

          -  Contra-indication to enoxaparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Imad ABI NASR, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ambroise Paré Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sud Francilien Hospital center</name>
      <address>
        <city>Corbeil</city>
        <state>Essonnes</state>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean MINJOZ</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ambroise Paré Hospital</name>
      <address>
        <city>Boulogne</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lagny center Hospital</name>
      <address>
        <city>Lagny sur Marne</city>
        <zip>77400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitié Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lariboisiére Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rangueil Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2006</study_first_submitted>
  <study_first_submitted_qc>December 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2006</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Anissa Bouzamondo</name_title>
    <organization>French Society of Cardiology</organization>
  </responsible_party>
  <keyword>enoxaparine</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>renal failure</keyword>
  <keyword>dose adaptation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

